Clinical trials: Moderate Asthma
Asthma, Healthy Volunteers
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729
RV1729 is a new medicine being developed for possible treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT01813084
- Testing
- RV1729 single dose, RV1729: 14 day repeat dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Respivert Ltd
Safety and Tolerability
PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD
This will be a randomized, open-label, active-controlled, single dose crossover study with either three or four treatment periods.
- Trial name
- NCT03307512
- Testing
- inhaled human insulin, Insulin Lispro (Humalog U-100)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Dance Biopharm Inc.
Asthma
Human Rhinovirus Infection and Airway Remodeling Mediators
In this study, the following subjects will be exposed to human rhinovirus (HRV): those with classification of mild-moderate asthma healthy control subjects.
- Trial name
- NCT01847768
- Testing
- GMP-grade HRV-39, Bronchoalveolar Lavage, Methacholine Inhalation Challenge
- Where
- Canada
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
TC-6987 for the Treatment of Mild to Moderate Asthma
This study is designed to determine whether TC-6987 improves respiratory function in subjects with asthma by reducing airway hyper-responsiveness and inflammation.
- Trial name
- NCT01296087
- Testing
- TC-6987
- Where
- 21 sites in United States
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
Health Adults, Asthma
Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate Asthma
This is a Phase I, randomized, double-blind, placebo-controlled, single ascending dose study evaluating HXN-1013 in healthy participants and participants with mild-to-moderate asthma.
- Trial name
- NCT07900568
- Testing
- HXN-1013
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Moderate Persistent Asthma, Severe Persistent Asthma
Expressions of TRPV1 in Airway of Asthmatics
The purpose of this study is to measure the density of a temperature-sensitive protein, named TRPV1, in the airway mucosa tissue of both non-asthmatic and moderate to severe persistent asthmatic patients.
- Conditions
- Moderate Persistent Asthma, Severe Persistent Asthma, Nodule Solitary Pulmonary, Pulmonary Atelectasis
- Trial name
- TRPV1 (NCT02952066)
- Testing
- Bronchial biopsy
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Lu Yuan Lee
Asthma, Healthy Volunteers
Evaluation of Safety, Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body in Healthy Adults and Adults With Asthma
This study evaluates the safety and tolerability of CHF10136 administered by inhalation in healthy adults and adults with asthma.
- Trial name
- NCT07851623
- Testing
- CHF10136
- Where
- 3 sites in United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in Healthy Volunteers and Adults With Asthma
Phase 1, 3-part study to assess safety, tolerability and PK of single and multiple doses of itraconazole administered as a dry powder for inhalation (PUR1900) in healthy subjects (parts 1 and 2) and a 2-period crossover study of…
- Trial name
- NCT03479411
- Testing
- Itraconazole Powder, Itraconazole 200 mg
- Where
- 2 sites in United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Pulmatrix Inc.
Atopic Dermatitis, Psoriasis
Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma
This Phase 1 study will investigate the safety and tolerability of EDP1867 in healthy volunteers, participants with atopic dermatitis, and, optionally, in participants with psoriasis and/or asthma.
- Conditions
- Atopic Dermatitis, Psoriasis, Asthma
- Trial name
- NCT04927195
- Testing
- EDP1867
- Where
- 7 sites in United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Evelo Biosciences, Inc.
Asthma
A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.
In relation to their severity, hepatic diseases can significantly modify drug absorption and disposition and consequently can interfere with drug efficacy and/or produce toxicity.
- Trial name
- NCT01266941
- Testing
- Inhaled FF 200mcg/GW642444M 25mcg
- Where
- 3 sites in Czechia, Slovakia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
ALLERGIC ASTHMA
A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe…
- Trial name
- NCT00283504
- Testing
- ANTI-IGE THERAPY (XOLAIR)
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of The King's Daughters
Asthma
Safety Study of Nebulized RNS60 to Treat Asthma.
The purpose of this study is two-fold. First, to determine whether nebulized RNS60 is safe in healthy human subjects and in subjects with mild asthma, in a single-dose administration.
- Trial name
- NCT01057498
- Testing
- RNS60, RNS60 - single dose
- Where
- 2 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Revalesio Corporation
Mild to Moderate Persistent Asthma
Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma.
This study aims to find out if AES ( Activation Energy Serum) , a blend of natural minerals , is effective and safe for the treatment of asthma if taken for 4 weeks .
- Trial name
- NCT01939951
- Testing
- Activation Energy Serum
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- California Allergy and Asthma Medical Group, Inc.